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Proliferation of bacterial pathogens in blood represents one of the most dangerous stages of infection. Growth in blood
serum depends on the ability of a pathogen to adjust metabolism to match the availability of nutrients. Although
certain nutrients are scarce in blood and need to be de novo synthesized by proliferating bacteria, it is unclear which
metabolic pathways are critical for bacterial growth in blood. In this study, we identified metabolic functions that are
essential specifically for bacterial growth in the bloodstream. We used two principally different but complementing
techniques to comprehensively identify genes that are required for the growth of Escherichia coli in human serum. A
microarray-based and a dye-based mutant screening approach were independently used to screen a library of 3,985
single-gene deletion mutants in all non-essential genes of E. coli (Keio collection). A majority of the mutants identified
consistently by both approaches carried a deletion of a gene involved in either the purine or pyrimidine nucleotide
biosynthetic pathway and showed a 20- to 1,000-fold drop in viable cell counts as compared to wild-type E. coli after 24
h of growth in human serum. This suggests that the scarcity of nucleotide precursors, but not other nutrients, is the key
limitation for bacterial growth in serum. Inactivation of nucleotide biosynthesis genes in another Gram-negative
pathogen, Salmonella enterica, and in the Gram-positive pathogen Bacillus anthracis, prevented their growth in human
serum. The growth of the mutants could be rescued by genetic complementation or by addition of appropriate
nucleotide bases to human serum. Furthermore, the virulence of the B. anthracis purE mutant, defective in purine
biosynthesis, was dramatically attenuated in a murine model of bacteremia. Our data indicate that de novo nucleotide
biosynthesis represents the single most critical metabolic function for bacterial growth in blood and reveal the
corresponding enzymes as putative antibiotic targets for the treatment of bloodstream infections.
Citation: Samant S, Lee H, Ghassemi M, Chen J, Cook JL, et al. (2008) Nucleotide biosynthesis is critical for growth of bacteria in human blood. PLoS Pathog 4(2): e37. doi:10.
1371/journal.ppat.0040037
Introduction
Bacteremia, characterized by the presence of pathogenic
bacteria in the bloodstream, is a major cause of morbidity
and mortality worldwide. Bacteremia often leads to sepsis and
death [1]. To survive in blood, bacterial pathogens must evade
a multitude of host defense mechanisms such as complement-
mediated lysis, phagocytosis and antimicrobial peptide-
mediated killing. The spectrum of complement resistance
mechanisms of bacteria is very wide and includes different
activities like antigenic variation, use of membrane proteins
to block binding of complement proteins and capsule
biosynthesis [2–5]. Most extracellular pathogens avoid phag-
ocytosis by synthesizing a protective capsule that helps to
evade recognition [6,7]. Direct degradation of antimicrobial
peptides and modiﬁcation of cell surface properties are the
major strategies used by bacteria to resist the bactericidal
activity of host antimicrobial peptides like the platelet-
derived thrombocidins in blood [8,9]. However, these
immune-evasion strategies are mostly pathogen-speciﬁc and
it is difﬁcult to use the underlying mechanisms as targets for
broad-spectrum antibiotics.
To proliferate in the various host niches that bacterial
pathogens invade during the course of infection they need to
adjust their metabolism to suit local nutrient availability. For
example, the amount of free iron in human blood is 10
 18 M
[10]. Most pathogens need 10
 6 to 10
 7 M iron for growth and
hence they use very complex and diverse strategies to acquire
and store iron in order to grow in this iron-limiting
environment of the host’s blood [11]. The most common
strategy of iron acquisition is the production of siderophores,
high-afﬁnity (10
30 M
 1) ferric iron-binding molecules that can
sequester iron from the host’s iron-binding proteins. Knock-
out of iron acquisition mechanisms has been shown to
attenuate the virulence of many bacteria [12,13]. However,
the uniqueness of blood as a niche for bacterial growth
extends far beyond iron limitation: low availability of certain
nutrients may deﬁne the ability of bacteria to proliferate in
blood. Although the absolute abundance of various metabo-
lites, such as amino acids and nucleotides, in human serum is
known [14,15], it is unclear which nutrients are freely
available and sufﬁcient and which are limiting for bacterial
growth in human serum.
Several previous reports described the importance of
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of infection. For instance, certain auxotroph mutants of
Salmonella [16–18], Staphylococcus aureus [19] or Streptococcus
pneumoniae [20] have been shown to be avirulent in murine
models of infection. These reports suggest that purines and
some amino acids are scarce in vivo. Also, the inactivation of a
potassium transporter in Vibrio vulniﬁcus [21] or of a
manganese, zinc and iron transporter in Streptococcus pyogenes
[22] have been shown to attenuate virulence of the respective
pathogens, suggesting that acquisition of some metal ions is
critical for growth in vivo. Notwithstanding the fact that most
of these genes were identiﬁed in non-exhaustive screens,
these studies only provide evidence of the limited availability
of the corresponding metabolites in the host. They do not
describe nutrient availability in various host compartments
invaded by the pathogens during infection. It is unclear
whether the reduced virulence of these mutants can be
attributed to their inability to grow speciﬁcally in blood. The
comprehensive identiﬁcation of genes that are critical,
speciﬁcally for the bloodstream growth of pathogens, has
never been attempted. Hence, crucial nutrient requirements
that need to be fulﬁlled during bacterial growth in blood are
essentially unknown.
Identiﬁcation of the limiting nutrients and of bacterial
genes that are critical for growth in blood can pinpoint
biosynthesis and acquisition strategies that are crucial during
the bacteremic stage of infection. Enzymes critical for
survival and proliferation of pathogenic bacteria in blood
can provide potential targets for treatment of bloodstream
infections.
To this end, we sought to identify genes required for the
growth of bacteria in human blood. We screened a
comprehensive gene-deletion library of the model Gram-
negative organism, Escherichia coli, for mutants unable to grow
in human serum. We found that de novo purine and
pyrimidine biosynthesis is the key pathway critical for E. coli
growth in serum, thereby revealing the limited availability of
nucleotide precursors as the major limitation for bacterial
growth in blood. Salmonella enterica, an important Gram-
negative pathogen, exhibited a similar requirement for de
novo biosynthesis of purines and pyrimidines for growth in
serum. Deletion of the corresponding genes in the evolution-
arily distant Gram-positive pathogen Bacillus anthracis dem-
onstrated the universal need for these two biosynthetic
pathways for bacterial growth in serum.
Results
Biosynthesis of Purines and Pyrimidines Is Critical for the
Growth of E. coli in Human Serum
Our major goal was to identify genes that are critical for
the survival and growth of bacteria in blood. Speciﬁcally, we
were interested in identifying genes that mediate adaptation
to the unique nutrient composition of blood rather than
those which facilitate immune evasion. Hence, in our
experiments we used human serum in which the function of
the complement system was inactivated by heat-treatment.
E. coli is a major cause of Gram-negative bacteremia in
hospitalized patients [23]. We used E. coli as an experimental
model for our initial experiments. Speciﬁcally, we used a
deﬁned library of 3985 E. coli single-gene deletion mutants
(‘‘Keio collection’’), where all non-essential genes of an E. coli
K12 laboratory strain BW25113 have been individually
replaced by a kanamycin-resistance cassette [24].
For the identiﬁcation of genes required for the growth of
bacteria in serum, we employed a genetic technique called
MGK (Monitoring of Gene Knockouts) [25]. MGK is a
microarray-based approach that uses the chromosomal ﬂanks
of inactivated genes as hybridization targets for custom-
designed oligonucleotide microarrays. It allows simultaneous
assessment of the relative abundance of thousands of mutants
in a population and identiﬁcation of genes whose inactiva-
tion is unfavorable for cell growth under selective conditions.
To apply MGK, mutants in the Keio collection were
individually grown and mixed at a similar ratio (see Protocol
S1 for details). The pooled library was grown in either serum
or in LB for 5 h (approximately 4 generations in serum)
(Figure 1A). Mutants lacking genes critical for growth in
blood are expected to be underrepresented in the resulting
population of cells grown in serum. Harvested cells were
allowed to re-grow in fresh LB medium in order to enrich the
population for viable cells and minimize isolation of genomic
DNA from dead cells. ‘‘MGK targets’’ corresponding to the
ﬂanks of inactivated genes were generated as described in
Protocol S1 using genomic DNA isolated from cells grown in
the reference (LB) and the selective (serum) conditions
(Figure 1A), and co-hybridized to an oligonucleotide micro-
array. Two independent MGK experiments (with dye-swap-
ping) were performed.
Twenty-two mutants with a potential growth defect in
serum were identiﬁed that consistently showed at least a 2-
fold reduction in the hybridization signal of the serum
sample as compared to the LB sample. Strikingly, the majority
of these mutants (15 out of 22) carried a deletion of a gene
involved in biosynthesis of either purines or pyrimidines
(Table 1 and Figure 2). This result suggested that the de novo
biosynthesis of purines and pyrimidines is crucial for the
growth of E. coli in human serum and that the scarcity of
nucleotide precursors is the major limiting factor for
bacterial growth in blood.
In an MGK experiment, thousands of mutants are grown
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Author Summary
Bacterial growth in the bloodstream is a common manifestation of a
number of bacterial infections. When growing in blood, bacteria not
only have to evade the host’s immune response, but also adjust
their metabolism to suit availability of nutrients. Although the
concentrations of various metabolites in human blood are known, it
is difficult to predict which nutrients are abundant and which are
scarce. To proliferate in human blood, bacteria need to synthesize
metabolites that are present in the limiting concentrations. For that,
they need to produce specific enzymes that are, thus, critical for the
bacterial growth in the bloodstream. We carried out a comprehen-
sive, genome-wide search for Escherichia coli genes that are essential
for growth in human serum. We found that inactivation of
nucleotide biosynthesis genes leads to a significant growth defect
in human serum not only for E. coli but also for two other
pathogens, Salmonella Typhimurium and Bacillus anthracis. The
results of this study demonstrate that the limiting amounts of the
nucleotide bases in human serum force invading pathogens to rely
on de novo nucleotide biosynthesis. Hence, our findings reveal
nucleotide biosynthesis enzymes as a possible target for the
treatment of bloodstream infections.together in a mixed population and growth characteristics of
each mutant can be potentially affected by metabolites
secreted by other cells. In addition, during re-growth in LB
media, the mutants that had growth defects in serum could
potentially catch up with the rest of the cells. To exclude this
scenario, we supplemented the MGK approach with an
independent screen involving replica growing of the 3,985
individual mutants from the Keio collection, arrayed in a 96-
well format, in serum and LB. The inherent turbidity of serum
prevents the use of optical density as a measure of bacterial
growth. Therefore, we used a dye, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), to detect viable cells
[26,27]. After overnight incubation of mutants in 96-well
plates in LB or in human serum, MTT dye was added to the
wells and the plates were incubated for another 4–5 h at 378C.
Overnight incubation of the cells in human serum before
addition of the MTT dye is expected to identify mutants that
are severely impaired in growth in serum rather than mutants
that show only modest growth defects. Live, actively growing
bacteria reduce MTT to a blue formazan precipitate resulting
in a deep blue color of the live serum cultures. The lack of a
blue color served as a qualitative indicator of the inability of
that mutant to grow in serum (Figure 1B).
The MTT screen identiﬁed 21 mutants that failed to grow
selectively in serum (Table 1 and Figure S1A). Of these, 17
mutants (81%) carried deletions of genes involved in the
nucleotide biosynthesis pathway. Fifteen of these 17 mutants
were also identiﬁed by the MGK analysis (Figure 2).
To verify the phenotypes of E. coli mutants identiﬁed by the
MGK and MTT screens, we followed their survival and growth
in human serum by determining the number of colony
forming units (cfu). This rigorous veriﬁcation showed that
mutants which lacked genes belonging to pathways other than
purine or pyrimidine biosynthesis (gcvR, rpoN, lysS, ihfB and
rseA identiﬁed only by the MGK analysis and nadB, panB, panC,
iscS identiﬁed only by the MTT assay) were apparently false
positives. Two mutants, ydaS and ydaT, carrying deletions in
genes with unknown function, found only in the MGK screen,
exhibited a mild growth defect (;10-fold reduction in cfu)
and were not studied further. Notably, however, all mutants
carrying a deletion in one of the pur or pyr genes showed a
signiﬁcant (20- to ;1,000-fold) reduction in the viable cell
number compared to wild-type E. coli after 24 h growth in
serum (Figure 3A). These included 15 pur or pyr mutants
identiﬁed by both MGK and MTT screens and two pur
mutants (guaA and guaB) identiﬁed only by the MTT screen
(Figure 2). Importantly, after incubation in serum, the cfu
counts of some mutants dropped below the initial inoculum
suggesting that these mutants not only had a growth defect,
but were actively dying in serum (Figure S1B). All pur and pyr
mutants grew well in LB medium, indicating that the growth
defect was serum-speciﬁc (Figure S1B). These results suggest
that nucleotide biosynthesis is a critical metabolic function
required for growth of E. coli in human serum and that the
scarcity of nucleic acid precursors, but not other metabolites,
is the key metabolic limitation for bacterial growth in human
blood.
Some of the E. coli nucleotide biosynthesis genes are
Figure 1. Identification of Genes Required for the Growth of E. coli in Human Serum
(A) Schematic representation of the identification of E. coli mutants from the Keio library with a growth defect in human serum using Monitoring of
Gene Knockouts (MGK).
(B) MTT dye-based screening for mutants with a growth defect in human serum. MTT was added after 24 h of growing the arrayed mutant library in 96-
well plates in either LB medium or serum. Mutants that could grow in serum generated a deep blue color by reducing MTT. The lack of a blue color in a
serum bacterial culture served as a qualitative indicator of the inability of that mutant to grow in serum.
doi:10.1371/journal.ppat.0040037.g001
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Nutrients Needed for Bacterial Bloodstream Growthorganized in operons. Therefore, their replacement by the
gene inactivation cassette could have a polar effect on the
expression of downstream genes. We tested and eliminated
this possibility by genetic-complementation studies. Struc-
tural regions of three operon-encoded E. coli genes carA, pyrE,
and guaB (the ﬁrst genes in the respective operons) (Figure
S1C), along with ;300 bp upstream regions that include their
native promoters, were cloned on a suitable vector and
introduced into corresponding mutant strains. The genet-
ically complemented E. coli strains (carA/pCarAEC, purE/
pPurEEC, guaB/pGuaBEC) thus obtained (Table S1) were tested
for growth in serum. Similarly complemented two strains of
gene deletions corresponding to monocistronic operons,
purA and pyrE (purA/pPurAEC and pyrE/pPyrEEC) were also
tested. All complemented E. coli mutant strains grew as well as
the wild type in serum (Figure 3B). This conﬁrmed that the
observed growth defect of the E. coli mutants in serum was
due to the lack of the corresponding gene and not the
manifestation of polar effects of gene replacement on
downstream genes.
In order to determine whether the observed growth defect
of the E. coli mutants in serum was indeed due to a limiting
supply of nucleic acid precursors, mutant growth was tested in
serum supplemented with an appropriate nucleobase, either
adenine or uracil, for the purine or pyrimidine biosynthesis
Figure 2. Genes Required for the Growth of E. coli in Human Serum
Identified by MGK and MTT Assay
Purine and pyrimidine nucleotide biosynthesis pathways in E. coli are
outlined. Genes that were identified to be essential for the growth of E. coli
in human serum by the MGK approach are underlined in black and those
identified by the MTT assay are underlined in grey. Essential genes, whose
deletions are absent from the defined library of E. coli mutants, are marked
by an asterisk. Genes whose deletion does not confer a growth defect in
serum are pyrI, ndk, purN and purT.T h epyrD mutant was not identified by
either screen, although it showed a growth defect in human serum.
doi:10.1371/journal.ppat.0040037.g002
Table 1. Mutants with a Growth Defect in Serum Identified by
MGK and MTT Dye-Based Colorimetric Screening of the Keio
Collection of E. coli Mutants
Gene MGK: Fold Reduction
in Fluorescence (LB/Serum)
MTT: (Luminosity wt/
Luminosity Mutant)
purA 3.8 6 0.23.5 14.29
a
purC 3.2 6 0.2 7.14
purD 4.0 6 0.1 3.57
purE 3.2 6 0.1 7.14
purF 2.2 6 0.2 3.86
purH 4.2 6 0.07 2.86
purK 2.8 6 0.1 3.23
purL 2.5 6 0.3 2.56
purM 2.5 6 0.1 4.55
guaA * 3.45
guaB * 2.33
pyrB 2.8 6 0.02 2.13
pyrC 3.5 6 0.07 2.63
pyrE 3.0 6 0.1 3.03
pyrF 2.8 6 0.1 3.45
carA 3.5 6 0.08 2.63
carB 3.0 6 0.07 3.12
ydaS 2.4 6 0.2 *
ydaT 2.4 6 0.07 *
gcvR
b 2.3 6 0.2 *
rpoN
b 2.3 6 0.3 *
lysS
b 3.9 6 0.09 *
ihfB
b 2.6 6 0.24 *
rseA
b 7.9 6 5.03 *
lipA
b * 2.38
panB
b * 2.44
panC
b * 2.33
nadB
b * 2.92
* Mutants not identified by MGK or MTT assay.
aValues are from a single determination.
bIdentified as false positives by subsequent tests.
doi:10.1371/journal.ppat.0040037.t001
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Nutrients Needed for Bacterial Bloodstream Growthmutants respectively. Addition of the appropriate nucleobase
to serum rescued the growth of the mutants (Figure 3C and
3D). This result conﬁrmed that the purine and pyrimidine
deﬁciency of human blood forces invading bacteria to rely on
the de novo biosynthesis of these metabolites.
Nucleotide Biosynthesis Pathways Are Critical for the
Growth of Salmonella enterica Serovar Typhimurium in
Human Serum
Virulent E. coli strains are extracellular enteric pathogens.
In contrast, the Gram-negative pathogen, Salmonella enterica
serovar Typhimurium (S. typhimurium), can also replicate
intracellularly in phagocytes. Previous studies have shown
that inactivation of nucleotide biosynthesis genes in S.
typhimurium attenuates its virulence [16,28,29]. This effect
has been attributed solely to the inability of the mutants to
colonize the intracellular niche. Our ﬁnding that the
inactivation of nucleotide biosynthesis genes prevents E. coli
from growing in human serum prompted us to test whether
Salmonella strains defective in purine or pyrimidine biosyn-
thesis show growth defects in serum. We tested the growth in
human serum of 14 different S. typhimurium mutants in which
pur or pyr genes were inactivated by transposon insertions
(Table S1). Most of the mutants showed a substantial growth
defect with 10- to ;100-fold or more reduction in viable cell
counts after 24 h of growth in human serum as compared to
the wild-type strain (Figure 3E). This result demonstrated that
de novo nucleotide biosynthesis is required for growth of S.
typhimurium in human serum and that the attenuated
virulence of such mutants may be due, at least in part, to
an inability of the pathogen to multiply in the host’s blood.
Gram-Positive Bacillus anthracis Requires Nucleotide
Biosynthesis for Growth in Human Serum
The systemic stage of the life-threatening anthrax infection
is characterized by the rapid growth of B. anthracis in the
host’s blood reaching up to10
8 bacteria/ml [30]. Few treat-
ment options are available for the late stages of anthrax
infections. Thus, it was of particular interest to investigate
whether purine and pyrimidine biosynthesis is critical for the
growth of Gram-positive B. anthracis in human serum, as was
observed for Gram-negative E. coli and S. enterica.
Mutants with deletions in either pur (purE and purK)o rpyr
(carA and pyrC) genes were constructed in B. anthracis Sterne
34F2 strain (pXO1
þ pXO2
 ) by allelic gene replacement. In
agreement with the observations made with Gram-negative
Figure 3. E. coli and S. typhimurium pur and pyr Mutants Have a Growth
Defect in Human Serum
(A) Ratios of the viable cell counts of 19 mutants identified by either MGK
or MTT assay as compared to wild-type E. coli after 24 h of growth in
human serum. p Values for each mutant relative to wild type were lower
than 0.001.
(B) Ratios of the viable cell counts of carA, pyrE, purA, purE and guaB
mutants (black bars) and the viable cell counts of carA/pCarAEC, pyrE/
pPyrEEC, purA/pPurAEC, purE/pPurEEC, guaB/pGuaBEC and wtþpBAD22
(grey bars) to those of wild-type E. coli following 24 h of growth in serum.
(C) Grey bars represent ratios of the viable cell counts of each pyrimidine
mutant to that of the wild-type E. coli after 24 h of growth in serum
supplemented with 1 mM uracil. Black bars represent these ratios in
serum without any nucleotide supplements.
(D) Grey bars represent ratios of the viable cell counts of each purine
mutant to that of the wild-type E. coli after 24 h of growth in serum
supplemented with 1 mM adenine. Black bars represent these ratios in
serum without any nucleotide supplements.
(E) Ratios of the viable cell counts of Tn5 transposon insertion mutants in
several pur and pyr genes of S. typhimurium to that of the wild type
determined after 24 h of growth in human serum by plating serial
dilutions on LB agar plates are represented by vertical bars. p Values for
each mutant relative to wild type were lower than 0.01. Error bars
indicate standard deviation (SD) for two independent experiments.
Statistical significance of the data was calculated using t-test in EXCEL.
doi:10.1371/journal.ppat.0040037.g003
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Nutrients Needed for Bacterial Bloodstream Growthpathogens, all of the B. anthracis mutants displayed a severe
growth defect in human serum: a 50- to ;1,000-fold decrease
in viable cell counts as compared to the wild type after 24 h
(Figure 4A). None of these mutants showed reduced growth in
LB medium (data not shown). Introduction of the plasmid
carrying the deleted gene or addition of appropriate
nucleobases rescued growth of these mutants in serum
(Figure 4B and 4C and Table S1).
This result demonstrates that the limiting amounts of
purines and pyrimidines in serum restrict the growth of B.
anthracis mutants and shows that de novo nucleotide biosyn-
thesis is a conserved requirement for the growth of at least
three bacterial species in human serum.
Inactivation of purE Significantly Attenuates Virulence of
B. anthracis
We hypothesized that the growth defect exhibited by B.
anthracis nucleotide biosynthesis mutants in serum would
manifest at the bacteremic stage of the infection resulting in
attenuated virulence. We used a murine model of anthrax
infection to test this hypothesis. For these experiments we
employed the B. anthracis Sterne strain, which causes lethal
infections in certain strains of inbred mice with pathologies
similar to systemic anthrax infection in humans [31,32].
Murine serum contains about 30-fold more cytidine as
compared to human serum (3 lM compared to 0.1 lM,
respectively) [14]. Therefore, it was not surprising that unlike
Figure 4. B. anthracis Nucleotide Biosynthetic Mutants Are Unable to Grow in Human Serum
(A) Ratios of the viable cell counts of the carA, pyrC, purE and purK mutants as compared to wild-type B. anthracis after 24 h of growth in human serum
(p value ,1 3 10
 5). Statistical significance of respective mutants relative to wild type was calculated using t-test in EXCEL.
(B) Ratios of the viable cell counts of purE, carA, pyrC and purK mutants (black bars) and the viable cell counts of purE/pPurEBA, carA/pCarABA, pyrC/
pPyrCBA, purK/pPurKBA,w tþ pHT304 and wt þ pHTSPAC (grey bars) to that of wild-type B. anthracis following 24 h of growth in serum.
(C) Grey bars represent ratios of the viable cell counts of each mutant to that of wild-type B. anthracis after 24 h of growth in serum supplemented with
1 mM adenine (purine mutants) and 1 mM uracil (pyrimidine mutants). Black bars represent these ratios in serum without any nucleotide supplements.
Error bars indicate SD of triplicate experiments.
(D) Attenuation of B. anthracis purE mutant in a murine model of bacteremia. Survival curves (Average Latency Survival) were derived from
transformation of daily LD50s estimated for mouse cohorts challenged intravenously with a dose range (10
3–10
8) of vegetative cells of the indicated B.
anthracis strains. Points on survival curves represent the mean 6 SEM values from three (Sterne, purE) or two (purE/pPurEBA, purK) different mouse
experiments. LD50 values shown in the graph represent the final values estimated at the end of the 6-day observation periods. Survival results were
unchanged when mice were observed for an additional 2 weeks.
doi:10.1371/journal.ppat.0040037.g004
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Nutrients Needed for Bacterial Bloodstream Growthin human serum, the pyrimidine biosynthesis mutants of B.
anthracis did not show any strong growth defect in murine
serum. However, as expected, purine biosynthesis mutants
purE and purK were defective for growth in murine serum
(Figure S3). The virulence of these two mutants was tested in a
murine infection model in which mice were challenged by
direct intravenous inoculation with increasing numbers of
bacilli and observed for survival following this experimental
bacteremia. The purE knockout mutant showed a dramatic
decrease in virulence as evidenced by ;3.5 log increase in
LD50 (p ¼ 0.002) and an increased survival of the challenged
mouse cohort (p , 0.001) as compared to mice challenged
with the wild-type Sterne strain (Figure 4D). Mice challenged
with the purE mutant remained healthy for the entire
additional 2-week period of observation and no bacteria
could be cultured from their blood or spleen. In contrast, a
purE mutant strain complemented with a plasmid carrying
the purE gene (purE/pPurEBA), was as virulent as the wild-type
Sterne strain. Unexpectedly, the purK mutant, which ex-
hibited a similar growth defect in serum in vitro as the purE
mutant was almost as virulent as the wild-type Sterne strain
(Figure 4D). This result showed that purE, but apparently not
purK, is essential for virulence of B. anthracis in mice and thus
reveals PurE as a putative antibiotic target for treatment of
anthrax bacteremia.
Discussion
In this paper we demonstrate that de novo nucleotide
biosynthesis is critical for survival and growth of bacteria in
human serum. A near exhaustive search using two independ-
ent screening strategies based on co-growth of E. coli gene
knockout mutants (MGK) and analysis of individual mutants
(MTT assay) applied to a comprehensive library of E. coli
mutants consistently pointed to the importance of mainly pur
and pyr genes for E. coli growth in human serum. The overlap
of the results of both screens identiﬁed 15 pur or pyr genes
that are required for successful growth of E. coli in human
serum (Figure 2). This result was conﬁrmed for two other
pathogenic species of bacteria, Gram-negative S. typhimurium
and Gram-positive B. anthracis.
Inactivation of most of the pur and pyr genes was
detrimental to bacterial growth in serum. Of the 13 non-
essential genes involved in the purine biosynthetic pathway in
E. coli, only two genes, purN and purT, were not identiﬁed as
being critical for growth in human serum (Figure 2). This is
not surprising because purN and purT both encode 5’-
phosphoribosylglycinamide transformylases with partly over-
lapping speciﬁcities [33], and their individual inactivation
should have little effect on cell growth. Of the 9 non-essential
genes involved in the pyrimidine biosynthetic pathway our
screens did not identify pyrI, pyrD, and ndk mutants. Upon
checking the growth of the pyrD mutant in serum, we
observed a signiﬁcant growth defect similar to that of the
mutants identiﬁed by the two screens (Figure S2A). The other
two mutants did not show strong phenotype in serum (Figure
S2A). This result was expected because pyrI encodes the
regulatory subunit of the aspartate carbamoyltransferase that
is not critical for the function of the enzyme [34], while Ndk is
a nucleoside-diphosphate kinase whose function is partly
redundant [35].
Iron acquisition genes are known to be important for
bacterial adaptation to growth in the iron-limiting environ-
ment of blood [10]. Yet no such mutants were identiﬁed in
our screens, and testing of several such individual E. coli
mutants (entA, fepE, fecA, and tonB) showed that their growth in
serum was not impaired (Figure S2B). One possible explan-
ation for this result is that heat inactivation destroys
transferrin-iron complexes and releases free iron that can
be used by bacteria.
The virulence of B. anthracis pur mutants has been
previously characterized in a murine peritoneal cavity
infection model [36]. Of all the mutants tested by Ivanovics
et al, only those lacking PurA or PurB activity were found to
be signiﬁcantly attenuated in mice. On the other hand, our
study shows that the B. anthracis purE mutant is signiﬁcantly
attenuated in virulence in a murine bacteremia model. These
results suggest that only certain enzymes in the purine
biosynthetic pathway can be potential targets for antibiotics.
The observed attenuation of the B. anthracis purE mutant not
only reveals the PurE enzyme as a novel target for the
development of anti-anthrax therapies, but also indicates that
deletion of purE in a fully virulent B. anthracis strain could be
a promising way to develop a live attenuated vaccine. In
contrast to the purE knockout strain, the purK mutant of B.
anthracis remained virulent and killed mice with an LD50 that
was only slightly higher than that of the wild-type Sterne
strain (Figure 4D). This result is not too surprising. PurK
catalyses the carboxylation of aminoimidazole ribonucleotide
(AIR) leading to an unstable intermediate, N
5-carboxyami-
noimdazole ribonucleotide (N
5-CAIR) [37,38], which is then
converted by PurE to carboxyaminoimidazole ribonucleotide
(CAIR). In vitro studies showed that a signiﬁcant fraction of
AIR can be non-enzymatically converted to N
5-CAIR at a high
concentration of bicarbonate [39]. The small amounts of N
5-
CAIR produced spontaneously in the purK mutant might
relieve the block in purine biosynthesis and rescue the
auxotrophy [40].
Our data strongly suggest that nucleotide biosynthesis is
the key metabolic pathway which is critical for proliferation
of bacterial pathogens in blood. It might be argued that our
conclusions could be deduced empirically from a known low
concentration of free nucleobases in the human blood
serum. Indeed, some previous studies pointed to a relative
scarcity of purines in blood [19]. However, other studies
suggested that purines and pyrimidines are sufﬁciently
abundant in this niche [41] and the importance of nucleotide
prototrophy for bacterial growth in human blood has never
been clearly demonstrated. Furthermore, the simple knowl-
edge of the nutrient composition of blood serum is not
sufﬁcient to predict which biochemical pathway will be rate-
limiting for bacterial growth in this niche. Thus, although
threonine, lysine, histidine, aromatic amino acid and ribo-
ﬂavin biosynthetic functions have been shown to be
important for bacterial infections, none of these pathways
appears to be critical for growth of bacteria in blood
[19,42,43].
Several previous studies have shown that pathogens require
nucleotide biosynthesis to establish a successful infection
[16,19,20,44,45]. Our study, however, is the ﬁrst to our
knowledge to demonstrate the importance of the de novo
synthesis of purines and pyrimidines for successful prolifer-
ation of pathogens speciﬁcally in blood. Reproduction of the
phenotypes associated with several identiﬁed gene knockouts
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Gram-positive pathogen B. anthracis, suggests the universal
importance of the nucleotide biosynthesis pathways for
growth of bacteria in the bloodstream. Indeed, as our data
shows, nucleotide biosynthesis may be the only metabolic
pathway that is universally required by bacterial pathogens
invading the blood. The corresponding enzymes thus appear
as putative antibiotic targets for curbing bacterial growth in
the bacteremia stage of infection. Of the enzymes identiﬁed
in this study as essential for growth of bacterial pathogens in
human blood, two, PyrC and PurE, are especially attractive as
targets for antibiotics. PyrC is a dihydroorotase that catalyzes
the reversible cyclization of carbamoyl aspartate to dihy-
droorotate [46]. The known dihydroorotases fall into two
major sequence classes. Class I enzymes are conserved among
fungi and most Gram-negative proteobacteria whereas higher
eukaryotes use class II dihydroorotases [47]. The limited
sequence conservation between the two types of PyrC (less
than 20%) [48] makes this enzyme an attractive target for the
treatment of Gram-negative and fungal infections. PurE
shows a higher degree of overall conservation between
bacteria and eukaryotes (Table S2). However, the catalytic
mechanisms of the bacterial and eukaryotic PurE enzymes are
substantially different. In bacteria, PurE utilizes N
5-CAIR to
make CAIR, whereas human PurE uses AIR and CO2 and does
not recognize N
5-CAIR as a substrate [49], pointing to a
signiﬁcant difference in the structure of the catalytic centers
in the bacterial and human enzymes. Given that the B.
anthracis purE mutant is avirulent, apparently due to inability
of bacteria to proliferate in blood, PurE emerges as an
attractive target for antibiotic therapies.
Nucleotides are important substrates not only for DNA
synthesis but also for DNA repair. Thus inhibitors targeting
the nucleotide biosynthesis functions identiﬁed in this study
can also impede the repair processes following bacterial DNA
damage induced by the host’s reactive oxygen intermediates
during infection.
Detailed exploration of PyrC and PurE as well as other
enzymes of the nucleotide biosynthesis pathways as potential
antibiotic targets may lead to development of new therapies
for treatment of bacterial bloodstream infections.
Materials and Methods
Bacterial strains, plasmids, and growth conditions. The collection
of gene knockout mutants of the E. coli strain BW25113 (Keio
collection) was obtained from Nara institute of Science and
Technology, Japan [24]. Wild-type Salmonella enterica serovar Typhi-
murium LT2 and isogenic Tn5 transposon insertion mutants were
obtained from the Salmonella Genetics Stock Center (Alberta,
Canada) (http://www.ucalgary.ca/;kesander/). B. anthracis Sterne
(pXO1
þ, pXO2
 ) wild-type strain [50] was used to construct pur and
pyr biosynthesis mutants. All the cloning procedures were carried out
using the OneShot TOP10 chemically competent E. coli cells
(Invitrogen) as the host. E. coli strain GM 2163 (New England Biolabs)
was used to obtain unmethylated plasmid DNA for transformation of
B. anthracis.
The vector pKS1 was used to construct deletion mutants in B.
anthracis [51]. Genetic complementation was carried out using
recombinant plasmids based on the pBAD22 vector for E. coli or
pHT304 vector [52] and pHTPSAC vector (H. Lee, unpublished data)
for B. anthracis. Construction of the plasmids used for genetic
complementation is outlined in Protocol S1. All primers used in this
study are listed in Table S3.
For all experiments involving growth of bacteria in serum, frozen
serum [Sterile ﬁltered type-AB human serum, Cat No. H4522 (Sigma)]
was thawed at 378C, heat-inactivated by incubation for 30 min at 568C
and buffered at pH 7.0 by addition of 1 M HEPES buffer (pH 5.2) to
the ﬁnal concentration of 5 mM. Control cultures were grown in
Luria-Bertani medium [53]. When necessary, antibiotics were added
at the following ﬁnal concentrations: kanamycin 30 lg/ml for E. coli or
100 lg/ml for B. anthracis, erythromycin 200 lg/ml for E. coli or 5 lg/ml
for B. anthracis and ampicillin 100 lg/ml for E. coli.
MGK selection and analysis. The MGK selection was carried out
essentially as described, by Smith et al [25], with minor modiﬁcations
speciﬁed in Protocol S1.
MTT dye-based testing. Mutants from the Keio collection were
replicated into 96-well plates containing 100 ll/well of LB supple-
mented with kanamycin. Plates were incubated overnight at 378C with
shaking. Cells were pelleted, washed once with PBS and resuspended
in 100 ll PBS. 1 ll culture from each well was inoculated into fresh
96-well plates containing either LB or heat-inactivated human serum
and incubated overnight with shaking at 378C. The next day, 10 llo f
0.5% dye solution [MTT; (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) in PBS] was added to each well and the plates
were incubated for 4–5 h at 378C. When quantitation was required,
plates were scanned using a Hewlett Packard Scanjet 5300C and
Adobe Photoshop was used to determine luminosity values in each
well (Figure S1A).
Testing of the B. anthracis mutants in the murine infection model.
B. anthracis Sterne strain, the purE and purK knockout mutants, or
genetically complemented mutant purE/pPurEBA (Table S1) were
grown in LB media, washed three times with PBS, and resuspended in
PBS at a cell density of ;5x10
8 cfu/ml. Cohorts of adult (8–10 weeks
old), female, NIH-Swiss mice, obtained from Frederick Cancer
Research Center, were inoculated via tail vein with 0.2 ml of PBS
containing serial 10-fold dilutions of vegetative B. anthracis cells (10
3-
10
8 cfu/mouse; 4–6 mice per bacterial dose in the studies repre-
sented). Mice were observed daily for 6 days for signs of fatal
outcome, using humane end points approved by the UIC institutional
animal care and use committee. To conﬁrm that the fatal infection
was caused by an inoculated strain, the presence of the correct gene
knockout was veriﬁed by PCR analysis of the bacterial colonies
recovered from blood or spleen of diseased animals. 50% lethal dose
(LD50) was estimated using the Spearman-Karber method [54]. The
LD50 data were converted to average latency survival (ALS) curves
using the described transformation [55]. Data were analyzed using
SigmaPlot software and log rank test of the signiﬁcance of differences
in survival curves and t-test analysis of the signiﬁcance of differences
in LD50s among animal cohorts challenged with different bacterial
strains.
Supporting Information
Figure S1. Identiﬁcation and Characterization of E. coli Mutants with
a Growth Defect in Human Serum
(A) A Hewlett Packard 5600C Scanjet was used to scan the 96-well
plate in Figure 1B after addition of 10 ll of MTT dye following 24 h of
growth in human serum. Luminosity values corresponding to each
well were determined using Adobe Photoshop. Ratios of corrected
luminosity (individual luminosity   background luminosity) for each
mutant to corrected luminosity for wild type were determined for
three independent experiments. p Values for all pur and pyr mutants
were lower than 0.001. Statistical signiﬁcance of respective mutants
relative to wild type was calculated using t-test in EXCEL. Back-
ground luminosity is determined from a well with only medium to
which MTT dye was added. Error bars indicate standard deviation of
triplicate experiments.
(B) Growth curves for four E. coli mutants, purK (open circles), purL
(ﬁlled inverted triangles), carA (open triangles) and carB (ﬁlled
squares) as compared to wild type (ﬁlled circles) in LB medium and
human serum. Viable counts were determined at regular time points
by plating serial dilutions of each culture.
(C) Organization of the carA and pyrE (pyrimidine biosynthesis) and
purA, guaB and purE (purine biosynthesis) genes on the E. coli genome.
Found at doi:10.1371/journal.ppat.0040037.sg001 (1.4 MB TIF).
Figure S2. Phenotype of Some E. coli Mutants Not Identiﬁed either by
MGK or MTT Assays
Ratios of the viable cell counts of the (A) pyrD, pyrI and ndk deletion
mutants of E. coli BW25113 and (B) the tonB, entA, fecA and fepE
deletion mutants of E. coli BW25113 to that of the wild-type parent
are shown after 24 h of growth in human serum.
Found at doi:10.1371/journal.ppat.0040037.sg002 (328 KB TIF).
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Nutrients Needed for Bacterial Bloodstream GrowthFigure S3. B. anthracis purE and purK Mutants Are Unable to Grow in
Murine Serum
(A) carA, pyrC, purE and purK mutants and wild-type B. anthracis grown
in murine serum or human serum for 24 h in 96-well plates and
stained with MTT. Control wells contain murine or human serum
with no cells.
(B) Ratios of the viable cell counts of the carA, pyrC, purE and purK
mutants of B. anthracis to that of the wild-type cells after 24 h growth
in murine serum.
Found at doi:10.1371/journal.ppat.0040037.sg003 (2.0 MB TIF).
Protocol S1. Supporting Materials and Methods
Identiﬁcation of E. coli mutants defective for growth in human serum
by MGK; construction of gene knockout mutants in B. anthracis;
veriﬁcation of phenotypes of individual mutant strains; and
construction of plasmids for genetic complementation.
Found at doi:10.1371/journal.ppat.0040037.sd001 (59 KB DOC).
Table S1. Plasmids and Strains Used in This Study
Found at doi:10.1371/journal.ppat.0040037.st001 (88 KB DOC).
Table S2. Amino Acid Sequence Similarity of the B. anthracis and
Homo sapiens Enzymes to the E. coli Nucleotide Biosynthesis Enzymes
Required for Growth in Blood Serum
Found at doi:10.1371/journal.ppat.0040037.st002 (48 KB DOC).
Table S3. Primers Used in This Study
Found at doi:10.1371/journal.ppat.0040037.st003 (60 KB DOC).
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